Merck EX-CELL® Series Serum-Free, Animal Component-Free Cell Culture Media

Overview

The Merck EX-CELL® Series represents a comprehensive portfolio of chemically defined, serum-free, and animal component-free cell culture media engineered for robust, reproducible, and scalable bioprocess applications. Each formulation is rigorously validated for specific host cell lines—including HEK293, Sf9/Sf21, BTI-TN-5B1-4 (High Five™), MDCK, PER.C6®, NSO, Sp2/0, and hybridoma cells—and optimized to support high-density suspension or adherent growth without exogenous serum supplementation. These media operate on the principle of replacing undefined biological components (e.g., fetal bovine serum) with precisely balanced combinations of recombinant proteins, synthetic lipids, trace elements, vitamins, amino acids, and energy substrates—enabling consistent physiological performance while eliminating batch-to-batch variability, adventitious agent risk, and regulatory complications associated with animal-derived materials. Designed for compliance-driven environments, the EX-CELL® platform supports early-stage research, process development, and GMP-aligned manufacturing of therapeutic proteins, viral vectors, vaccines, and monoclonal antibodies.

Key Features

• Chemically defined formulations with full transparency of all raw material sources and concentrations
• Animal component-free (ACF) and low-protein (<11 mg/L in EX-CELL® 610) profiles compliant with ICH Q5D and USP <1043> guidance
• Validated long-term passaging stability: ≥20 passages for HEK293, Sf9/Sf21, MDCK, PER.C6®, and High Five™ cells; ≥25 passages for Sp2/0; ≥50 passages for NSO under suspension conditions
• High viability maintenance (>95% post-passage) and rapid proliferation kinetics (e.g., Sf9 doubling time: 20–24 h in EX-CELL® TiterHigh)
• Enhanced functional output: Elevated recombinant protein titers in EX-CELL® 405 vs. Sf9 in serum-containing media; superior mAb yield in EX-CELL® 610 vs. FBS-supplemented controls
• Scalable compatibility—from static flasks and roller bottles to stirred-tank bioreactors up to 2,000 L

Sample Compatibility & Compliance

The EX-CELL® media line demonstrates broad yet selective compatibility across mammalian, insect, and hybridoma expression systems. EX-CELL® 293 supports stable HEK293 suspension cultures for transient transfection and lentiviral production. EX-CELL® 405 and 420 are qualified for baculovirus expression vector system (BEVS) workflows using High Five™ and Sf9/Sf21 cells, respectively. EX-CELL® MDCK enables serum-free adherent expansion of canine kidney epithelial cells for influenza vaccine production. EX-CELL® VPRO is specifically formulated for PER.C6® suspension culture in roller bottle systems, meeting EMA/FDA expectations for human diploid cell line propagation. All formulations are manufactured under ISO 13485-certified quality systems, with full documentation packages (CoA, CoC, TSE/BSE statements) available. The series aligns with regulatory expectations for animal-free sourcing per EU Directive 2001/83/EC Annex I and supports GLP/GMP audit readiness.

Software & Data Management

While EX-CELL® media are consumables rather than instrument-based platforms, Merck provides integrated digital support via the MERCK Life Science Technical Resource Portal, offering downloadable protocols, lot-specific QC data sheets, bioprocess scalability guides, and comparative performance benchmarks. Each product lot includes traceable analytical certificates with pH, osmolality, glucose/lactate profiles, and endotoxin levels (<0.25 EU/mL). For clients operating under FDA 21 CFR Part 11 requirements, Merck delivers electronic records with audit trails for media selection, qualification reports, and change control documentation upon request—ensuring full data integrity across technology transfer and regulatory submissions.

Applications

• Therapeutic protein and monoclonal antibody production in CHO, NSO, Sp2/0, and hybridoma systems
• Viral vector manufacturing (LV, AAV, RV) using HEK293 and PER.C6® cells
• Recombinant glycoprotein and enzyme expression in insect cell platforms (Sf9, Sf21, High Five™)
• Influenza and rabies vaccine production using MDCK and BHK-21 cells
• Cell banking and master/working cell stock maintenance under serum-free conditions
• Process characterization and DOE studies requiring minimal media-induced variability

FAQ

Are EX-CELL® media compatible with single-use bioreactors?

Yes—EX-CELL® formulations have been successfully deployed in wave bags, rocking-motion platforms, and stainless-steel stirred-tank reactors up to pilot scale. Validation data for gas transfer efficiency and shear sensitivity are available upon request.

Do any EX-CELL® products require pre-conditioning or supplementation?

No—EX-CELL® 405, 420, TiterHigh, VPRO, NSO, Sp2/0, and 610 are ready-to-use formulations. No additional protein, lipid, or growth factor supplementation is required.

How is sterility assurance maintained during manufacturing?

All EX-CELL® media undergo terminal filtration through 0.1 µm membranes and are aseptically filled under ISO 5 cleanroom conditions. Sterility testing follows USP <71> and Ph. Eur. 2.6.1 protocols.

Can EX-CELL® media be used for clinical-grade manufacturing?

Yes—multiple EX-CELL® formulations (e.g., 293, VPRO, 610) have supported Phase III clinical supply and commercial manufacturing under cGMP. Full regulatory support files—including extractables/leachables data and elemental impurity profiling—are available for qualified users.